Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG (MOLN) is a clinical-stage biotechnology pioneer advancing DARPin therapeutics for oncology and radiopharmaceutical applications. This page provides investors and industry observers with official company announcements, clinical trial milestones, and strategic partnership updates.
Access the latest developments in MOLN's Radio-DARPin Therapy platform, Switch-DARPin candidates, and ophthalmology programs. Our curated news collection enables efficient tracking of regulatory filings, preclinical data disclosures, and financial results without promotional commentary.
Key content categories include clinical trial progress, collaborative research updates with partners like Orano Med, and technology platform innovations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for centralized access to Molecular Partners' verified announcements. For comprehensive analysis of MOLN stock performance, visit Stock Titan's dedicated market data section.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) provides an update following Novartis' quarterly earnings call, where CEO Vas Narasimhan mentioned that the Emergency Use Application (EUA) for ensovibep requires additional clinical data for FDA authorization. The ongoing omicron wave complicates clinical investigations. Novartis is coordinating with the FDA to design a potential Phase 3 study to gather necessary data for EUA or full approval. Molecular Partners continues to develop its DARPin therapeutics in collaboration with major pharmaceutical companies.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that late-breaker data from the EMPATHY study of ensovibep will be presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases in Lisbon from April 23-26, 2022. Dr. N. Kumarasamy will present interim results from the phase II/III study focused on mild-to-moderate COVID-19 patients. Additionally, a symposium on COVID-19 variants and DARPin therapeutic efficacy will occur on April 26, featuring insights from Novartis and Molecular Partners' executives.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company, announced participation in the Kempen Life Sciences investor conference on April 20-21, 2022. CFO Andreas Emmenegger and COO Michael Stumpp will present on April 20 at 16:30 CET (10:30 AM EDT). The company focuses on developing DARPin therapeutics, a new class of custom-built protein drugs aimed at addressing unmet medical needs in areas like infectious disease and oncology. More details will be available on the Molecular Partners website.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that all shareholder motions were approved during its recent Annual General Meeting. Key outcomes included the re-election of the Board of Directors, with Bill Burns remaining as Chairman. KPMG AG Zurich was confirmed as statutory auditors for 2022. Shareholders authorized the Board to increase share capital until April 2024 and approved the annual financial statements for 2021. The meeting was conducted virtually due to COVID-19 regulations, without physical attendance.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced significant preclinical findings for MP0317, its second immuno-oncology candidate, published in Cancer Immunology Research. MP0317 targets FAP and CD40 to foster localized immune activation in tumors while minimizing systemic toxicity. The study demonstrates that MP0317 effectively induces tumor-localized immune activation, potentially offering a wider therapeutic window compared to traditional CD40-targeting therapies. Currently undergoing a Phase 1 clinical trial, initial results are anticipated in late 2022.
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) has announced the details of its Annual General Meeting (AGM) scheduled for April 13, 2022, at 2 PM CET. The meeting will be held virtually due to ongoing pandemic concerns, allowing shareholders to participate only through written or electronically submitted instructions to an independent proxy. Key upcoming financial events include the Interim Management Statement Q1 2022 on May 12, 2022, and Half-year results 2022 on August 25, 2022. Molecular Partners is focused on developing DARPin therapeutics for various medical applications.
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) released its financial results for 2021, noting a total revenue of CHF 9.8 million and a net loss of CHF 63.8 million. The company received CHF 150 million from Novartis following positive Phase 2 results for ensovibep, a DARPin therapeutic for COVID-19. Ensovibep has FDA Fast Track designation, with plans for global Phase 3 trials. Molecular Partners maintains strong financial health, projecting cash runway into 2025. The company aims to broaden its pipeline, including oncology and virology programs, while preparing for key regulatory submissions.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm, announced CEO Patrick Amstutz's participation in two investor events in March 2022. Key dates include the Credit Suisse London Global Healthcare Conference on March 1-2, and a Fireside chat at the Cowen Health Care Conference on March 9. Additionally, the FY 2021 annual report will be published on March 15, followed by an investor conference call on March 16. Webcasted presentations will be accessible via the company's website.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced that CEO Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation is scheduled for February 16, 2022, at 9:20 am ET. This clinical-stage biotech company specializes in developing DARPin therapeutics, a novel class of custom-built protein drugs aimed at addressing healthcare challenges. Their work spans infectious disease, oncology, and ophthalmology, with partnerships among leading pharmaceutical companies.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced that its partner Novartis requested Emergency Use Authorization (EUA) from the U.S. FDA for ensovibep, a DARPin antiviral therapeutic candidate aimed at treating COVID-19. This request builds on positive Phase 2 trial results from the EMPATHY study involving 407 symptomatic patients infected with SARS-CoV-2. Ensovibep is designed to inhibit the virus's entry into cells by targeting the spike protein, showing potential advantages in treating COVID-19.
FAQ
What is the current stock price of MOLECULAR PARTNERS (MOLN)?
What is the market cap of MOLECULAR PARTNERS (MOLN)?
